Immatics (NASDAQ:IMTX - Get Free Report) traded down 3.7% during trading on Thursday . The company traded as low as $10.62 and last traded at $10.69. 543,089 shares changed hands during trading, an increase of 3% from the average session volume of 526,042 shares. The stock had previously closed at $11.10.
Immatics Trading Down 5.3 %
The stock has a market capitalization of $889.78 million, a P/E ratio of -8.54 and a beta of 0.69. The stock's 50 day simple moving average is $11.75 and its 200 day simple moving average is $10.57.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of IMTX. Vestal Point Capital LP bought a new position in shares of Immatics in the 4th quarter worth about $22,113,000. Goldman Sachs Group Inc. lifted its position in shares of Immatics by 324.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,548,909 shares of the company's stock worth $16,310,000 after buying an additional 1,183,860 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Immatics by 13.3% in the 4th quarter. Wellington Management Group LLP now owns 6,352,929 shares of the company's stock worth $66,896,000 after buying an additional 747,772 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Immatics by 44.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,334,169 shares of the company's stock worth $24,579,000 after buying an additional 719,634 shares during the last quarter. Finally, RTW Investments LP lifted its position in shares of Immatics by 75.7% in the 4th quarter. RTW Investments LP now owns 1,484,911 shares of the company's stock worth $15,636,000 after buying an additional 639,911 shares during the last quarter. 64.41% of the stock is currently owned by institutional investors.
About Immatics
(
Get Free Report)
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Immatics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immatics wasn't on the list.
While Immatics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
